BRAF and melanoma: Interestingly, the relationship between survival and tumor driven mutational status has been extensively investigated: BRAF-mutated melanoma has been associated with a shorter survival in patients with both metastatic (68, 69) and early-stage disease (70, 71); moreover, for patients with metastatic BRAF-mutated melanoma receiving BRAF inhibitors, a worse prognosis has been also associated with alterations in the thrombophilic status, such as high D-dimer levels at baseline (72, 73).